Loading...
•
Dec 31, 2023
Cardiff Oncology Q4 2023 Earnings Report
Announced financial results for Q4 and full year 2023, provided a business update, and first patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC.
Key Takeaways
Cardiff Oncology reported having $75 million in cash and cash equivalents as of December 31, 2023, sufficient to fund operations into Q3 2025. The company's operating expenses increased to $45.9 million for the full year ended December 31, 2023. First patient was dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC.
First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC with the support of FDA and clinical execution from Pfizer Ignite.
Interim topline data from first-line RAS-mutated mCRC trial is expected in mid-2024.
New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients.
Cash and equivalents of $75 million as of December 31, 2023, projected runway into Q3 2025.
Revenue by Segment
Forward Guidance
Cardiff Oncology believes its current cash resources are sufficient to fund its operations into Q3 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...